1111636-35-1

1111636-35-1 structure

Name: PF-04880594
Chemical Name: 3-((4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl)amino)propanenitrile
CAS Number: 1111636-35-1
Molecular Formula: C₁₉H₁₆F₂N₈
Molecular Weight: 394.381
Catalog: Signaling Pathways MAPK/ERK Pathway Raf
Create Date: 2016-04-24 20:10:57
Modify Date: 2025-09-21 21:17:53
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity[1].

Name	3-((4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl)amino)propanenitrile
Synonyms	PF-04880594 3-[[4-[1-(2,2-Difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]propanenitrile PF-04880594/PF04880594 3-({4-[1-(2,2-Difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]-2-pyrimidinyl}amino)propanenitrile Propanenitrile, 3-[[4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-

Description	PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> Raf
Target	Braf CRAF
In Vitro	PF-04880594 (100 nM, 48 h) causes ERK activation and stimulation of IL-8 release, both of which are blocked by PD-0325901 (HY-10254) treatment[1]. Western Blot Analysis[1] Cell Line: HL-60 Concentration: 100 nM alone or in combination with 100 nM PD-0325901 Incubation Time: 48 h Result: Induced ERK phosphorylation and induced IL-8 production. PD-0325901 treatment blocked the induction.
In Vivo	PF-04880594 (10 mg/kg) induces ERK phosphorylation and BRAF-CRAF dimerization in multiple epithelial tissues in mice and the induction can be attenuated by PD0325901[1]. PF-04880594 (0-40 mg/kg, twice daily for 3 weeks) induces epithelial hyperplasia in mice and the induction is prevented by PD0325901[1]. Animal Model: Nude mice[1] Dosage: 10 mg/kg alone or in combination with 0.5 mg/kg PD-0325901 Administration: An am and pm dose on day 1 and then an am dose on day 2 approximately 2 hours before the animals were necropsied and the tissues harvested Result: Induced ERK phosphorylation in urinary bladder, tongue, skin, and esophagus tissues.The induction of ERK phosphorylation was attenuated by cotreatment with 0.5 mg/kg PD0325901. Animal Model: Nude mice (6–8 weeks old)[1] Dosage: 10, 20 and 40 mg/kg alone or in combination with 0.1, 0.3, 0.5, 1.0, or 2.5 mg/kg PD-0325901 Administration: Twice daily for 3 weeks Result: Tissues treated with the RAF inhibitor alone display the microscopic pathology typical of unopposed BRAF inhibition. Hyperplasia in nonglandular stomach epithelium was blocked by PD-0325901.
References	[1]. Torti VR, et al. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. Mol Cancer Ther. 2012 Oct;11(10):2274-83.

Density	1.5±0.1 g/cm3
Boiling Point	666.3±65.0 °C at 760 mmHg
Molecular Formula	C₁₉H₁₆F₂N₈
Molecular Weight	394.381
Flash Point	356.8±34.3 °C
Exact Mass	394.146606
PSA	108.10000
LogP	1.24
Vapour Pressure	0.0±2.0 mmHg at 25°C
Index of Refraction	1.710
Storage condition	-20℃

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H315-H319-H335
Precautionary Statements	P280-P304 + P340 + P312-P305 + P351 + P338-P337 + P313
RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1111636-35-1	1808094-07-6
1415637-72-7	1173177-11-1
2218484-75-2	2227425-05-8
893556-85-9	1801333-55-0
1079400-07-9	2080306-28-9
941879-25-0	899990-29-5
95312-33-7	941879-29-4
95312-49-5	941968-73-6
941927-26-0	941987-82-2
941927-32-8	941987-86-6